Cap Innov'Est

Rhythm Diagnostic Systems is a healthcare technology company specializing in remote patient monitoring solutions. Its primary product, MultiSense®, enables continuous monitoring of patients' physiological parameters, both in hospitals and at home, aiming to improve patient pathways and enhance care efficiencies. The company serves primarily hospitals and institutions seeking to optimize patient care and reduce hospital stays. It generates recurring revenues through a 'fee for service' business model and offers additional services to support healthcare professionals in effectively using its technology.

VistaCare is a French company specializing in innovative medical devices for treating acute and chronic wounds. It develops, manufactures, and distributes products designed to enhance patient quality of life and simplify caregiver routines by reducing treatment times and hospital stays.

Opencell is a company founded in 2015, building on an open source telco billing project initiated in 2007. It specializes in providing an integrated revenue management platform designed to manage subscription and usage-based billing across various industries, including telecommunications, cloud services, IoT, and utilities. The platform addresses the limitations of both complex legacy billing systems and simplistic SaaS solutions, offering a more flexible and agile monetization approach. With over 40 successful implementations worldwide, Opencell's open-source solution enables organizations to efficiently administer their subscription and usage-based revenues, making sophisticated billing accessible to a diverse range of businesses.

Defymed is a leading innovator in the development of implantable medical devices that enhance drug delivery systems across various therapeutic applications. The company focuses on site-specific delivery of therapeutics to minimize adverse events associated with current standard care, thereby improving disease management and patient quality of life. Defymed has developed two pioneering technologies: MailPan®, a device for physiologic cell encapsulation, and ExOlin®, a targeted drug delivery device currently in clinical use. With exclusive technology and expertise, Defymed's medical devices serve as a platform for multiple therapeutic applications, including type 1 diabetes, hemophilia, and cancer management. The company is certified ISO13485:2016 and has established a robust global network of experts in cell therapy and drug delivery. Defymed has received numerous accolades in Europe and the USA for its innovative approaches to enhancing patient care.

Syndivia is a biotechnology company focused on developing innovative cancer therapeutics aimed at treating patients with challenging cancer indications. The company specializes in targeted antibody-drug conjugates (ADCs), designed to optimize drug-to-antibody ratios, thereby enhancing antitumor efficacy and safety. Syndivia's vision centers on leveraging the unique properties of tumor hallmarks and the tumor microenvironment to deliver effective treatments that improve outcomes for cancer patients.

Urania Therapeutics is a biopharmaceutical company focused on the identification and development of readthrough compounds aimed at treating genetic diseases and certain cancers. The company utilizes a proprietary structure-based drug design platform to create novel therapeutic treatments that address conditions caused by mutations, specifically those involving premature stop codons during protein synthesis. By enabling the production of full-length, functional proteins, Urania Therapeutics targets a range of monogenic disorders, including Duchenne muscular dystrophy and cystic fibrosis, as well as cancers linked to nonsense mutations. Through its innovative approach, the company seeks to restore normal protein production, offering potential new solutions for patients with these challenging genetic conditions.

Exeliom is a clinical-stage biopharmaceutical company based in Dijon, France, focused on developing innovative microbial therapies that utilize commensal bacteria as therapeutic agents. Founded in 2016, Exeliom aims to unlock the therapeutic potential of gut microbiota to enhance health and longevity. The company specializes in creating a new class of medicines known as Live Biotherapeutics, which are designed to deliver microbiome-based immunotherapy for conditions such as inflammatory bowel diseases and cancer, with an initial focus on Crohn's Disease. By harnessing the role of microbiota in the immune system, Exeliom strives to provide patients with advanced treatments that improve their quality of life.

Medsenic SAS is a privately held company based in Paris, France, specializing in the development and manufacture of drugs aimed at treating autoimmune diseases, including systemic lupus erythematosus and graft-versus-host disease. Founded in 2010, the company also produces arsenic trioxide, which is utilized in the treatment of acute promyelocytic leukemia, contributing to significant remissions and potential cures for serious conditions. Medsenic focuses on innovative therapeutic solutions to address unmet medical needs in the field of autoimmune and hematological disorders.

Opencell is a company founded in 2015, building on an open source telco billing project initiated in 2007. It specializes in providing an integrated revenue management platform designed to manage subscription and usage-based billing across various industries, including telecommunications, cloud services, IoT, and utilities. The platform addresses the limitations of both complex legacy billing systems and simplistic SaaS solutions, offering a more flexible and agile monetization approach. With over 40 successful implementations worldwide, Opencell's open-source solution enables organizations to efficiently administer their subscription and usage-based revenues, making sophisticated billing accessible to a diverse range of businesses.

Inoviem Scientific SAS is a contract research biotechnology company based in Strasbourg, France, founded in 2011. The company specializes in developing advanced technologies for analyzing drug-target interactions under physiological conditions using human tissues. Its proprietary technologies include physiological intermolecular modulation spectroscopy, which examines the interactions of exogenous molecules with tissue, and techniques for isolating protein complexes and reconstructing their three-dimensional structures. Inoviem Scientific offers a range of services across the drug development spectrum, including target identification, lead optimization, preclinical and clinical development, and biomarker testing. The company serves a diverse clientele, including private and academic laboratories, as well as the pharmaceutical and biotechnology industries. By leveraging its innovative technologies, Inoviem Scientific aims to enhance the drug development process, improve the selection of lead compounds, and reduce attrition rates, ultimately accelerating the delivery of new therapeutic solutions.

PeptiMimesis specializes in developing transmembrane therapeutic peptides. Its innovative approach enables the identification of peptidomimetic candidates that interfere with the hetero- and/or homodimerization of target receptors, primarily focusing on oncology and immuno-oncology targets. The company is open to collaborations with pharmaceutical partners.

FiberMetrix specializes in innovative solutions for real-time radiation dose monitoring in both medical and industrial applications. The company develops advanced dosimetry technology that utilizes patented optical fiber technology to provide automatic feedback on radiation exposure for patients and occupational settings. Its expertise in radiation detection and dosimetry allows FiberMetrix to create a range of sensors, including fully integrated and handheld devices with variable geometry, which enable precise and remote measurement of radiation doses. These systems enhance awareness of radiation exposure and improve the safety and efficiency of clinical examinations and imaging applications across various radiation-based sectors.

WizzVet operates an interactive platform facilitating continuous learning and knowledge exchange among veterinary professionals. It offers web conferences with new courses weekly, earning participants continuing education credits.

PeptiMimesis specializes in developing transmembrane therapeutic peptides. Its innovative approach enables the identification of peptidomimetic candidates that interfere with the hetero- and/or homodimerization of target receptors, primarily focusing on oncology and immuno-oncology targets. The company is open to collaborations with pharmaceutical partners.

Opencell is a company founded in 2015, building on an open source telco billing project initiated in 2007. It specializes in providing an integrated revenue management platform designed to manage subscription and usage-based billing across various industries, including telecommunications, cloud services, IoT, and utilities. The platform addresses the limitations of both complex legacy billing systems and simplistic SaaS solutions, offering a more flexible and agile monetization approach. With over 40 successful implementations worldwide, Opencell's open-source solution enables organizations to efficiently administer their subscription and usage-based revenues, making sophisticated billing accessible to a diverse range of businesses.

Defymed is a leading innovator in the development of implantable medical devices that enhance drug delivery systems across various therapeutic applications. The company focuses on site-specific delivery of therapeutics to minimize adverse events associated with current standard care, thereby improving disease management and patient quality of life. Defymed has developed two pioneering technologies: MailPan®, a device for physiologic cell encapsulation, and ExOlin®, a targeted drug delivery device currently in clinical use. With exclusive technology and expertise, Defymed's medical devices serve as a platform for multiple therapeutic applications, including type 1 diabetes, hemophilia, and cancer management. The company is certified ISO13485:2016 and has established a robust global network of experts in cell therapy and drug delivery. Defymed has received numerous accolades in Europe and the USA for its innovative approaches to enhancing patient care.

Inoviem Scientific SAS is a contract research biotechnology company based in Strasbourg, France, founded in 2011. The company specializes in developing advanced technologies for analyzing drug-target interactions under physiological conditions using human tissues. Its proprietary technologies include physiological intermolecular modulation spectroscopy, which examines the interactions of exogenous molecules with tissue, and techniques for isolating protein complexes and reconstructing their three-dimensional structures. Inoviem Scientific offers a range of services across the drug development spectrum, including target identification, lead optimization, preclinical and clinical development, and biomarker testing. The company serves a diverse clientele, including private and academic laboratories, as well as the pharmaceutical and biotechnology industries. By leveraging its innovative technologies, Inoviem Scientific aims to enhance the drug development process, improve the selection of lead compounds, and reduce attrition rates, ultimately accelerating the delivery of new therapeutic solutions.

Bionext S.A. is a biotechnology company based in Strasbourg, France, specializing in bioinformatics and the development of advanced software tools aimed at enhancing drug discovery and development processes. Founded in 2009, Bionext focuses on creating a three-dimensional molecular visualization software that integrates big data, cloud computing, and OMICS data. This platform enables pharmaceutical and biotechnology companies to visualize and simulate drug interactions within human cells, thereby improving the understanding and prediction of drug efficacy and side effects. Additionally, Bionext offers a virtual screening platform that models cellular environments to facilitate high-throughput screening and early assessments of new compounds in pharmaceuticals, cosmetics, and agri-food sectors. The company is dedicated to addressing critical challenges in drug development, including drug profile assessment and repurposing strategies.